The biochemistry of fetal lung development.

Mitchell Kresch, I. Gross

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Surfactant therapy for RDS is likely to become widespread in the near future. Animal data indicate that this will not preclude a role for hormonal acceleration of lung maturation. In studies with prematurely delivered and ventilated fetal rabbits, Fiascone et al. have shown that the administration of betamethasone antenatally improves lung compliance, as does intratracheal administration of excess amounts of adult rabbit natural surfactant. If the two therapies are combined, however, an additive effect is observed. This suggests that some of the effects of glucocorticoids on lung compliance are not related to surfactant. Prior glucocorticoid therapy may provide a benefit that differs from that of surfactant therapy because steroids mature the lungs anatomically and enhance nonsurfactant-related tissue compliance. It is also possible that surfactant therapy itself may be more effective in the presence of larger and increased numbers of alveoli. It thus seems likely that in the future both hormonal enhancement of lung maturation and surfactant therapy may be used in combination to further reduce the morbidity and mortality from RDS.

Original languageEnglish (US)
Pages (from-to)481-507
Number of pages27
JournalClinics in Perinatology
Volume14
Issue number3
StatePublished - Sep 1 1987

Fingerprint

Fetal Development
Surface-Active Agents
Biochemistry
Lung
Lung Compliance
Glucocorticoids
Therapeutics
Rabbits
Betamethasone
Compliance
Steroids
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Kresch, Mitchell ; Gross, I. / The biochemistry of fetal lung development. In: Clinics in Perinatology. 1987 ; Vol. 14, No. 3. pp. 481-507.
@article{2ffb7ed747564f4494fe9c07291dc636,
title = "The biochemistry of fetal lung development.",
abstract = "Surfactant therapy for RDS is likely to become widespread in the near future. Animal data indicate that this will not preclude a role for hormonal acceleration of lung maturation. In studies with prematurely delivered and ventilated fetal rabbits, Fiascone et al. have shown that the administration of betamethasone antenatally improves lung compliance, as does intratracheal administration of excess amounts of adult rabbit natural surfactant. If the two therapies are combined, however, an additive effect is observed. This suggests that some of the effects of glucocorticoids on lung compliance are not related to surfactant. Prior glucocorticoid therapy may provide a benefit that differs from that of surfactant therapy because steroids mature the lungs anatomically and enhance nonsurfactant-related tissue compliance. It is also possible that surfactant therapy itself may be more effective in the presence of larger and increased numbers of alveoli. It thus seems likely that in the future both hormonal enhancement of lung maturation and surfactant therapy may be used in combination to further reduce the morbidity and mortality from RDS.",
author = "Mitchell Kresch and I. Gross",
year = "1987",
month = "9",
day = "1",
language = "English (US)",
volume = "14",
pages = "481--507",
journal = "Clinics in Perinatology",
issn = "0095-5108",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Kresch, M & Gross, I 1987, 'The biochemistry of fetal lung development.', Clinics in Perinatology, vol. 14, no. 3, pp. 481-507.

The biochemistry of fetal lung development. / Kresch, Mitchell; Gross, I.

In: Clinics in Perinatology, Vol. 14, No. 3, 01.09.1987, p. 481-507.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The biochemistry of fetal lung development.

AU - Kresch, Mitchell

AU - Gross, I.

PY - 1987/9/1

Y1 - 1987/9/1

N2 - Surfactant therapy for RDS is likely to become widespread in the near future. Animal data indicate that this will not preclude a role for hormonal acceleration of lung maturation. In studies with prematurely delivered and ventilated fetal rabbits, Fiascone et al. have shown that the administration of betamethasone antenatally improves lung compliance, as does intratracheal administration of excess amounts of adult rabbit natural surfactant. If the two therapies are combined, however, an additive effect is observed. This suggests that some of the effects of glucocorticoids on lung compliance are not related to surfactant. Prior glucocorticoid therapy may provide a benefit that differs from that of surfactant therapy because steroids mature the lungs anatomically and enhance nonsurfactant-related tissue compliance. It is also possible that surfactant therapy itself may be more effective in the presence of larger and increased numbers of alveoli. It thus seems likely that in the future both hormonal enhancement of lung maturation and surfactant therapy may be used in combination to further reduce the morbidity and mortality from RDS.

AB - Surfactant therapy for RDS is likely to become widespread in the near future. Animal data indicate that this will not preclude a role for hormonal acceleration of lung maturation. In studies with prematurely delivered and ventilated fetal rabbits, Fiascone et al. have shown that the administration of betamethasone antenatally improves lung compliance, as does intratracheal administration of excess amounts of adult rabbit natural surfactant. If the two therapies are combined, however, an additive effect is observed. This suggests that some of the effects of glucocorticoids on lung compliance are not related to surfactant. Prior glucocorticoid therapy may provide a benefit that differs from that of surfactant therapy because steroids mature the lungs anatomically and enhance nonsurfactant-related tissue compliance. It is also possible that surfactant therapy itself may be more effective in the presence of larger and increased numbers of alveoli. It thus seems likely that in the future both hormonal enhancement of lung maturation and surfactant therapy may be used in combination to further reduce the morbidity and mortality from RDS.

UR - http://www.scopus.com/inward/record.url?scp=0023404751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023404751&partnerID=8YFLogxK

M3 - Review article

C2 - 3311536

AN - SCOPUS:0023404751

VL - 14

SP - 481

EP - 507

JO - Clinics in Perinatology

JF - Clinics in Perinatology

SN - 0095-5108

IS - 3

ER -